NDA 217677 · Springworks
Ogsiveo
Nirogacestat Hydrobromide · Oral · Gamma Secretase Inhibitor
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Nov 27, 2023: To treat adults with progressing desmoid tumors who require systemic treatment
Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Nov 27, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
923
302 serious, 8 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 1, 2026.
OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. OGSIVEO is a gamma secretase inhibitor indicated for adult patients with progressing desmoid tumors who require systemic treatment. ( 1 )
Mechanism: Nirogacestat is a gamma secretase inhibitor that blocks proteolytic activation of the Notch receptor. When dysregulated, Notch can activate pathways that contribute to tumor growth.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 27, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
3 products under this application
- OGSIVEO · NIROGACESTAT HYDROBROMIDE EQ 100MG BASE · TABLET, ORAL · Prescription
- OGSIVEO · NIROGACESTAT HYDROBROMIDE EQ 150MG BASE · TABLET, ORAL · Prescription
- OGSIVEO · NIROGACESTAT HYDROBROMIDE EQ 50MG BASE · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Nirogacestat Hydrobromide" as an intervention, any sponsor and status, largest first.
- A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by SurgeryActive, not recruiting
Children's Oncology GroupResearch network
NCT04195399 · 31 participants · Start Oct 7, 2020 · Primary completion Mar 31, 2026
Drug: Nirogacestat Hydrobromide · For: Desmoid Fibromatosis; Recurrent Desmoid Fibromatosis; Unresectable Desmoid Fibromatosis
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 98 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea323
- nausea203
- fatigue177
- rash120
- product dose omission issue93
- headache90
- vomiting82
- stomatitis61
- cough50
- pruritus48
- alopecia45
- intentional underdose42
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 15 |
| 2023 | 22 |
| 2024 | 563 |
| 2025 | 156 |
| 2026 | 164 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ogsiveo (Nirogacestat Hydrobromide)
2024 spending
$20.0M
Beneficiaries
154
766 claims
Per beneficiary
$130,006
$278.36 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $428,916 |
| 2024 | $20,020,868 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Springworks
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.